How Ozempic Lowers Blood Sugar
Ozempic (semaglutide) is a GLP-1 receptor agonist injected weekly. It mimics the GLP-1 hormone, which the body releases after eating, to regulate glucose levels in type 2 diabetes. It reduces average blood sugar (A1C) by 1-2% over 6-12 months in clinical trials, outperforming placebo and some oral meds like metformin alone.[1][2]
Triggering Insulin When Needed
Ozempic prompts the pancreas to release more insulin only when blood sugar rises, such as after meals. This glucose-dependent action avoids hypoglycemia risk compared to insulin injections, which work constantly.[1]
Blocking Glucagon to Cut Liver Glucose
It suppresses glucagon, a hormone from the pancreas that signals the liver to release stored glucose. Less glucagon means the liver produces less sugar between meals, stabilizing fasting levels.[2]
Slowing Digestion for Steady Absorption
By delaying stomach emptying, Ozempic slows carb breakdown and sugar entry into the bloodstream. This prevents post-meal spikes, with effects noticeable within hours of the first dose.[1]
Weight Loss as a Bonus Effect
Patients lose 5-15% body weight on average due to reduced appetite from brain signaling. Less fat improves insulin sensitivity, further aiding blood sugar control—key since obesity worsens type 2 diabetes.[2][3]
How Long Until It Works and Peak Effect
Blood sugar drops within 1-2 weeks, with full benefits by 4-8 weeks at 1mg weekly dose (starting at 0.25mg). Adjustments depend on tolerance; max is 2mg.[1]
Compared to Other Diabetes Drugs
Unlike metformin (targets liver glucose) or SGLT2 inhibitors (increase urine sugar excretion), Ozempic hits multiple pathways at once. Head-to-head trials show it reduces A1C more than DPP-4 inhibitors like Januvia.[2]
Sources
[1]: Novo Nordisk Ozempic Prescribing Information
[2]: FDA Ozempic Label
[3]: NEJM SUSTAIN Trials